Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Pneumothorax-I01:26

Pneumothorax-I

A pneumothorax is a condition where air builds up in the space between the lung and the chest wall, causing the lung to collapse. This condition arises when air enters the space between the parietal and visceral pleura, disrupting the negative pressure essential for lung inflation. This can lead to a partial or complete collapse of the lung.
Pneumothorax can be even further classified as spontaneous, traumatic, and tension pneumothorax.
Pneumothorax-II01:27

Pneumothorax-II

Pneumothorax is a medical condition defined by the buildup of air in the pleural space between the lungs and the chest wall. This accumulation of air can lead to partial or complete lung collapse, resulting in a range of clinical manifestations. Understanding the clinical presentation and effective management strategies is crucial for healthcare professionals in providing timely and appropriate care to individuals with pneumothorax.
Clinical Manifestations:
Pulmonary Embolism I: Introduction01:29

Pulmonary Embolism I: Introduction

Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
Pulmonary Embolism III: Nursing Management01:27

Pulmonary Embolism III: Nursing Management

A pulmonary embolism occurs when a thrombus, amniotic fluid, tumor tissue, fat, or air embolus blocks one or more pulmonary arteries. Effective nursing management and patient education are crucial for improving outcomes and preventing recurrence.Nursing management starts with obtaining a comprehensive patient history, particularly noting any history of deep vein thrombosis (DVT). Assess for clinical manifestations, including dyspnea, chest pain, crackles, heart murmurs, and signs of right-sided...
Pulmonary Embolism I: Introduction01:19

Pulmonary Embolism I: Introduction

A blood clot, or thrombus, is a semi-solid mass composed of fibrin, platelets, and red blood cells. When it forms within a vessel, it can obstruct blood flow, known as thrombosis. If part of the clot detaches, it becomes an embolus that can travel and block distant vessels. When this occurs in the pulmonary arteries, it causes a condition known as pulmonary embolism (PE).Origin and ImpactMost often, the embolus originates from a thrombus in the deep veins of the lower limbs, a condition called...

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Developmental Profile and Variability in Preschool-Age Children With Down Syndrome.

Journal of intellectual disability research : JIDR·2026
Same author

Clinical and patient-reported outcomes after drug-coated balloon angioplasty for femoropopliteal peripheral artery disease.

VASA. Zeitschrift fur Gefasskrankheiten·2026
Same author

Ultrasound-Facilitated, Catheter-Directed Fibrinolysis for Acute Pulmonary Embolism.

The New England journal of medicine·2026
Same author

Post-pulmonary embolism cardiac impairment and chronic thromboembolic pulmonary hypertension after ultrasound-assisted catheter-directed thrombolysis for acute pulmonary embolism.

Clinical research in cardiology : official journal of the German Cardiac Society·2026
Same author

Sirolimus-Coated Balloon Angioplasty for Infrainguinal Artery Disease.

The New England journal of medicine·2026
Same author

Correction: Ficany et al. Epistaxis Prevention, Treatment, and Future Perspectives for Hereditary Hemorrhagic Telangiectasia. <i>J. Clin. Med.</i> 2025, <i>14</i>, 7724.

Journal of clinical medicine·2026

Video Experimental Relacionado

Updated: May 9, 2026

Chronic Thromboembolic Pulmonary Hypertension and Assessment of Right Ventricular Function in the Piglet
09:22

Chronic Thromboembolic Pulmonary Hypertension and Assessment of Right Ventricular Function in the Piglet

Published on: November 5, 2015

12.7K

La embolia pulmonar masiva es un tipo de embolia pulmonar masiva.

Nils Kucher1, Elisa Rossi, Marisa De Rosa

  • 1Cardiovascular Division, Department of Medicine, University Hospital Zurich, Zurich, Switzerland.

Circulation
|January 25, 2006
PubMed
Resumen

Los resultados del tratamiento de la embolia pulmonar masiva (EP) muestran que la trombólisis no mejoró la supervivencia, mientras que los filtros de vena cava inferior (IVC) pueden reducir la mortalidad. Se necesita más investigación para la eficacia del filtro IVC en pacientes con EP masiva.

Más Videos Relacionados

Establishment of a Minimally Invasive Rat Model of Pulmonary Embolism Using Autologous Blood Clots
08:02

Establishment of a Minimally Invasive Rat Model of Pulmonary Embolism Using Autologous Blood Clots

Published on: October 26, 2024

922
A Porcine Model of Acute Autologous Pulmonary Embolism
07:44

A Porcine Model of Acute Autologous Pulmonary Embolism

Published on: September 7, 2024

927

Videos de Experimentos Relacionados

Last Updated: May 9, 2026

Chronic Thromboembolic Pulmonary Hypertension and Assessment of Right Ventricular Function in the Piglet
09:22

Chronic Thromboembolic Pulmonary Hypertension and Assessment of Right Ventricular Function in the Piglet

Published on: November 5, 2015

12.7K
Establishment of a Minimally Invasive Rat Model of Pulmonary Embolism Using Autologous Blood Clots
08:02

Establishment of a Minimally Invasive Rat Model of Pulmonary Embolism Using Autologous Blood Clots

Published on: October 26, 2024

922
A Porcine Model of Acute Autologous Pulmonary Embolism
07:44

A Porcine Model of Acute Autologous Pulmonary Embolism

Published on: September 7, 2024

927

Área de la Ciencia:

  • Cardiología Cardiología.
  • Medicina Pulmonar La medicina pulmonar es el tratamiento de las enfermedades pulmonares.
  • Medicina de cuidados críticos Medicina de cuidados críticos.

Sus antecedentes:

  • La embolia pulmonar masiva aguda (EP) se asocia con una alta tasa de mortalidad.
  • Las terapias complementarias como la trombólisis y los filtros de la vena cava inferior (IVC) se utilizan en el manejo masivo de la EP.
  • Comprender el impacto de estas terapias en los resultados clínicos es crucial.

Objetivo del estudio:

  • Investigar la utilización de la trombólisis y la colocación de filtros IVC en pacientes con PE masiva.
  • Evaluar el efecto de estas terapias adyuvantes en los resultados clínicos de pacientes con EP masiva.

Principales métodos:

  • Análisis de los datos del Registro Internacional Cooperativo de Embolismo Pulmonar (ICOPER).
  • Se incluyeron 2392 pacientes con EP aguda, identificando 108 (4,5%) con EP masiva (presión arterial sistólica <90 mm Hg).
  • Comparación de los resultados entre los pacientes que recibieron trombólisis, embolectomía o filtros IVC frente a aquellos que no lo hicieron.

Principales resultados:

  • Los pacientes con EP masiva tuvieron una tasa de mortalidad a los 90 días del 52,4% en comparación con el 14,7% de los pacientes con EP no masiva.
  • La terapia trombolítica no redujo significativamente la mortalidad a los 90 días (46,3% frente a 55,1%) o las tasas de PE recurrentes (12% frente a 12%).
  • La colocación del filtro de la vena cava inferior (IVC) se asoció con una reducción de la mortalidad a los 90 días (razón de riesgo, 0.12) y ningún evento de PE recurrente.

Conclusiones:

  • Dos tercios de los pacientes con EP masiva en ICOPER no recibieron trombolisis o embolectomía.
  • La trombólisis no demostró un beneficio en la mortalidad ni una reducción en la EP recurrente a los 90 días.
  • La reducción potencial de la mortalidad asociada con los filtros IVC justifica una mayor investigación.